

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME A. Simon Pickard		POSITION TITLE Assistant Professor	
eRA COMMONS USER NAME pickarda			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Alberta, Edmonton, Alberta, Canada	B. Comm.	1991	Business
University of Alberta, Edmonton, Alberta, Canada	B.Sc Pharm	1996	Pharmacy
University of Alberta, Edmonton, Alberta, Canada	Ph.D.	2002	Pharmacy & Pharmaceutical Sciences

A. Positions and Honors**Positions and Employment**

05/1997 – 06/2001: Staff Pharmacist, Broadmoor Pharmacy, Sherwood Park, Alberta

01/1998 – 06/2001: Research Assistant, Institute of Health Economics, Edmonton, Alberta

01/1999 – 04/2000: Teaching Assistant, Faculty of Pharmacy, University of Alberta

11/2000 – 04/2001: Research Associate, Health Technology Assessment Unit, Alberta Heritage Foundation for Medical Research, Edmonton, Alberta, Canada

09/2001 - Present: Assistant Professor, Dept. of Pharmacy Practice, Univ. of Illinois at Chicago, Chicago, IL.

09/2003 - Present: Assistant Professor, Dept. of Pharmacy Administration, UIC, Chicago, IL.

09/2005 – Present: Assistant Director, Center for Pharmacoeconomics Research, UIC, Chicago, IL.

Honors

1988, 1989: Certificate of Merit Award (University of Alberta)

1997: Institute of Pharmacoeconomics Graduate Assistantship Award (University of Alberta)

1999: J. Gordin Kaplan Travel Award (University of Alberta)

1999-00: Parke Davis Doctoral Fellowship in Pharmacy Practice Research

2000 - 2001: Alberta Heritage Foundation for Medical Research – Full-Time Studentship – Incentive Award, Health Research

2000 – 2001: Rx&D – HRF (Health Research Foundation)/CIHR (Canadian Institutes of Health Research) Graduate Research Scholarship in Pharmacy

2003: New Investigator Award, International Society for Quality of Life Research

2003: Best Overall Oral Presentation, International Society for Quality of Life Research Annual Conference

B. Selected peer-reviewed publications (in chronological order)

1. **Pickard AS**, Johnson JA, Lau F, Penn A, Noseworthy T. The replicability of the SF-36 by the SF-12 in stroke patients. *Stroke* 1999;30:1213-1217.

2. Spooner CH, Pickard AS, Menon D. A systematic review of quinolone, cephalosporin and macrolide use in ambulatory care. *Clinical Therapeutics* 1999;21:1951-1972.

3. Johnson JA, Coons SJ, Hays RD, **Pickard AS**. Health status and satisfaction with pharmacy services. *American Journal of Managed of Care* 1999;5(2):163-170.

4. **Pickard AS**, Johnson JA, Farris KB. The impact of pharmacist interventions on health-related quality of life. *The Annals of Pharmacotherapy* 1999;33:1167-72.

5. Johnson JA, **Pickard AS**. Comparison of the EQ-5D and SF-12 in a general population survey in Alberta, Canada. *Medical Care* 2000;38(1):115-121.

6. Spooner CH, **Pickard AS**, Menon D. Edmonton Quality Assessment Tool for Drug Utilization Reviews - EQUATDUR-2: The development of a scale to assess the methodological quality of a drug utilization review. *Medical Care* 2000;38(9):948-958.
7. Johnson JA, **Pickard AS**. Alberta-based SF-12 summary scores. *Archives of Hellenic Medicine* 2001;18(2):136-147.
8. **Pickard AS**, Schumock GT. Aspirin Use May Change Cost-effectiveness of COX-2 Inhibitors. *Archives of Internal Medicine* 2002;162(22):2637-9.
9. Park HY, Schumock GT, **Pickard AS**, Akhras K. A structured review of the relationship between microalbuminuria and cardiovascular events in patients with diabetes mellitus and hypertension. *Pharmacotherapy* 2003;23(12):1611-1616.
10. **Pickard AS**, Johnson JA, Feeny DH, Carriere KC, Shuaib A, Nasser AM. Agreement between self- and proxy assessment in stroke: a comparison of generic HRQL measures. *Stroke* 2004;35(2):607-12.
11. Nutescu E, **Pickard AS**, Blackburn J, Schumock GT, Ansell J, Wittkowsky A. The implications of direct thrombin inhibitors for anticoagulation clinics. *Pharmacotherapy* 2004;24(9):1204-1212.
12. **Pickard AS**, Nau D, McKercher P, Schumock GT. The importation of prescription medications: the experiences, opinions and intended behaviors of US community pharmacists *Journal of American Pharmacists Association* 2004;44:666-672.
13. **Pickard AS**, Topfer LA, Feeny DF. A structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia. *Journal of the National Cancer Institute Monographs*. 2004(33):102-125.
14. **Pickard AS**, Johnson JA, Feeny DH. Responsiveness of the SF-36, HUI and EQ-5D in Stroke. *Quality of Life Research*. 2005;14:207-219.
15. **Pickard AS**, Wang Z, Walton SM, Lee TA. Do different preference-based algorithms for the SF-36 and SF-12 potentially alter decision-making when applied to cost utility analysis? *Health Outcomes and Quality of Life* 2005;3:11.
16. **Pickard AS**, Knight SJ. A conceptual framework for understanding differences in proxy perspectives. *Medical Care* 2005;43(5):493-499.
17. Kramer KM, Bennett CL, **Pickard AS**, Lyons EA, Wolf MS, McKoy JM, Knight SJ. Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. *Clinical Prostate Cancer* 2005;4(1):15-23.
18. McCarthy M Jr, Chang CH, **Pickard AS**, Giobbie-Hurder A, Price DD, Jonasson O, Gibbs J, Fitzgibbons R, Neumayer L. Visual analog scales for assessing surgical pain. *Journal of the American College of Surgeons* 2005;201(2):245-52.
19. McCarthy M Jr, Jonasson O, Chang CH, **Pickard AS**, Giobbie-Hurder A, Gibbs J, Edelman P, Fitzgibbons R, Neumayer L. Assessment of patient functional status after surgery. *Journal of the American College of Surgeons* 2005;201(2):171-8.
20. **Pickard AS**, Hung SY, McKoy JM, Witt WP, Arseven A, Sharifi R, Wu Z, Knight SJ, McWilliams N, Schumock GT, Bennett CL. Opportunities for disease state management in prostate cancer. *Disease Management* 2005;8(4):235-44.
21. Calhoun EA, Schumock GT, McKoy JM, **Pickard S**, Fitzner KA, Heckinger EA, Powell EF, McCaffrey KR, Bennett CL. Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited. *Pharmacoeconomics* 2005;23(8):767-75.
22. McKoy JM, Lyons EA, Obadina E, Carson K, **Pickard AS**, Schellhammer P, McLeod D, Boyd CE, McWilliams N, Sartor O, Schumock GT, McCaffery K, Bennett CL. Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. *Journal of Clinical Oncology* 2005;23(34):8894-905.
23. Wolf MS, Fitzner KA, Powell EF, McCaffrey KR, **Pickard AS**, McKoy JM, Lindenberg J, Schumock GT, Carson KR, Ferreira MR, Dolan NC, Bennett CL. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among veterans. *Journal of Clinical Oncology* 2005;23(34):8877-83.
24. **Pickard AS**, Dalal MR, Bushnell D. A comparison of depressive symptoms in stroke and primary care: applying Rasch models to evaluate the CES-D scale. *Value in Health* 2006;9(1):59-64.

C. Research Support

Ongoing Research Support

1R03 CA108395-01 Pickard (PI) 4/01/04 – 3/31/06

National Cancer Institute/National Institutes of Health (NCI/NIH)

Proxy perspectives on quality of life in prostate cancer

The aims of this study are to elicit proxy assessments of patients with prostate cancer in order: 1) To determine the extent of agreement between HRQL assessments performed by an informal caregiver from the perspective of the patient compared to their assessment of patient HRQL from the caregiver's own viewpoint; 2) To assess the extent of agreement between patient self-assessment in relation to two proxy assessed perspectives; and 3) To evaluate whether different proxy perspectives result in differences in HRQL assessment that are statistically significant and clinically meaningful.

HHS290200500381, Task Order No. 1 9/30/05 – 6/30/06

AHRQ - Center for Outcomes and Evidence

Outcomes of COPD Management

The specific aims of this project are to: review datasets available to examine outcomes of COPD medication management; identify and prioritize key medication management issues in COPD; evaluate outcomes (COPD exacerbations, mortality) associated with inhaled corticosteroids (ICS) compared to concomitant use of ICS with long-acting beta agonists.

Role: Co-Investigator

Economic and clinical outcomes of pharmaceutical policies in the VA system Pickard: PI

3/01/05 – 3/30/06

IPA - Edward Hines Jr. VA Hospital/Midwest Center for Health Services Research

The objective of this research is to identify clusters of comorbid conditions in veterans in the VA system and explore the incremental effect of various co-morbidities, such as having COPD compared to COPD plus arthritis, on the cost of illness and mortality rates. In addition, the ameliorating effects of medications on clinical outcomes and mortality will be investigated, such as NSAID use in the aforementioned example.

Biological and Self-Reported Measures of Psychological Stress among Informal Caregivers of Patients with Prostate Cancer: A Pilot Study 8/01/2004 – 7/31/2005

American Cancer Society – Institutional Research Grant (Northwestern University)

The aim of this pilot study is to determine the feasibility, performance, and comparability of stress biomarkers in caregivers of patients with prostate cancer as compared to caregiver-reported survey measures of psychological stress and how such measures are related to patient health outcomes. Moreover, we also seek to determine if sociodemographic differences in the health-related quality of life of veterans with prostate cancer can be explained in part by differences in caregiver burden.

Role: Co-Investigator

Completed Research Support (Past 3 Years)

Outcomes Analysis of Diabetes Treatments in Using VA Data 9/01/03 – 3/01/05

Takeda Pharmaceuticals North America Inc

This is a retrospective case control analysis of patient outcomes across different treatment courses for diabetes.

Role: Co-Investigator

Reimportation of Pharmaceuticals: Pharmacists Perceptions and Intended Behaviors 01/01/04 – 12/31/04

AstraZeneca

The purpose of this cross-sectional survey is to provide insights into the circumstances and interventions such as FDA certification that would most dramatically influence pharmacists' behaviors.

Role: Co-Investigator

Proxy Perspectives on Health Related-Quality of Life: pilot study/structured cognitive interviews

9/01/03 – 02/01/04

Veteran Affairs Health Services Research and Development. Locally Initiated Projects (LIPs)

Role: Co-Investigator

Implications of Oral Direct Thrombin Inhibitors for Anticoagulation Clinics (Investigator Initiated Research Grant) Pickard: PI 3/01/03 – 12/01/04

AstraZeneca

The purpose of this survey-based research is to describe the services and activities presently performed at anticoagulation clinics across the USA, to determine how oral DTIs are expected to impact those clinics, and to elicit how clinical providers intend to re-organize their clinics in response.

Microalbuminuria and cardiovascular events: a systematic review of the clinical outcomes and estimation of potential economic impact 1/01/02 – 12/31/03

Pharmacia

The purpose of the study is to describe and quantify the relationship between microalbuminurea and cardiovascular events in both diabetic and nondiabetic patients with hypertension, and to provide preliminary information on the economic impact of microalbuminurea in these patient populations.

Role: Co-Investigator

The Influence of Depression on Agreement between Proxy and Patient Self-Assessment in Stroke using the EQ-5D and SF-6D Pickard: PI 3/15/02 – 3/15/03

EuroQol Foundation (Rotterdam, The Netherlands)

The study aims to provide evidence on the reliability of using proxy respondents to report changes in HRQL on behalf of patients. The results are anticipated to assist clinicians and researchers in selecting HRQL outcome measures for use in clinical practice and research settings such as clinical trials, and generate evidence on the reliability of proxy respondents in cross-sectional and longitudinal studies.